Drug Discovery Day 2025

11:00 AM - 11:30 AM ET

What’s next for genetic testing and drug discovery?

Drug companies regularly turn to genetic data to look for new therapeutic targets. That’s made drug discovery an appealing turn for genetic testing companies – with varying degrees of success. Join Endpoints to hear from experts about which pharmaceutical partnerships have been fruitful for gene testing companies, which have proven more challenging, and what comes next.

Katherine Stueland

President & CEO

GeneDx

Cristen Willer

Executive Director of Genomics & Health Data Mining

Regeneron

Jared Whitlock

Features Editor

Endpoints News

11:35 AM - 12:20 PM ET

Bridging the chasm between discovery and development: Insights from your partners' C-suite

Accelerating and streamlining the discovery of both small molecules and biologics is challenging. One of the toughest parts of that process is transitioning your most promising programs into the clinic — it's the time when innovators often feel alone and under pressure to prove efficacy before they run out of resources. But it needn’t be such a lonely journey. We have assembled three leading discovery and development partners to provide insights on how collaboration can help you reach your endpoints faster and more efficiently.